Table 4.
Risk analysis of acute rejection and de novo DSA.
| Univariate HR (95% CI) |
p-Value | Multivariate HR (95% CI) |
p-Value | ||
|---|---|---|---|---|---|
| Biopsy proven Acute Rejection | Induction therapy: r-ATG/Basiliximab | 1.27 (0.78–2.08) | 0.335 | 1.16 (0.69–1.96) | 0.585 |
| Recipient age | 0.99 (0.98–1.01) | 0.423 | |||
| BMI | 1.02 (0.97–1.08) | 0.420 | |||
| sex: male/female | 1.39 (0.95–2.03) | 0.091 | 1.33 (0.88–1.99) | 0.172 | |
| DM | 1.29 (0.88–1.90) | 0.196 | |||
| HLA 1 mismatch | 1.17 (1.00–1.37) | 0.045 | 1.01 (0.83–1.24) | 0.896 | |
| HLA 2 mismatch | 1.71 (1.31–2.23) | <0.001 | 1.74 (1.24–2.44) | 0.001 | |
| PRA ≥ 50% | 0.28 (0.04–1.98) | 0.201 | |||
| WIT | 1.12 (0.98–1.29) | 0.091 | 1.11 (0.97–1.27) | 0.149 | |
| CIT | 1.00 (1.00–1.01) | 0.199 | |||
| Donor age | 1.01 (1.00–1.03) | 0.105 | |||
| creatinine | 1.14 (0.52–2.51) | 0.749 | |||
| sex: male/female | 0.75 (0.53–1.06) | 0.104 | |||
| de novo DSA † | Induction therapy: r-ATG/Basiliximab | 6.83 (1.87–25.0) | 0.004 | 6.78 (1.80–25.5) | 0.005 |
| Recipient age | 0.97 (0.93–1.03) | 0.313 | |||
| BMI | 0.99 (0.81–1.21) | 0.925 | |||
| sex: male/female | 0.36 (0.10–1.30) | 0.119 | |||
| DM | 0.29 (0.04–2.34) | 0.246 | |||
| HLA 1 mismatch | 1.24 (0.70–2.22) | 0.461 | |||
| HLA 2 mismatch | 2.91 (1.06–8.00) | 0.038 | 2.72 (1.02–7.29) | 0.046 | |
| WIT | 1.06 (0.64–1.75) | 0.822 | |||
| CIT | 1.08 (1.00–1.02) | 0.147 | |||
| Donor age | 0.99 (0.94–1.04) | 0.720 | |||
| creatinine | 2.19 (0.40–12.2) | 0.369 | |||
| sex: male/female | 1.59 (0.44–5.79) | 0.480 |
r-ATG, rabbit anti-thymocyte globulin; BMI, body mass index; DM, diabetes mellitus; HLA, human leukocyte antigen; PRA, panel reactive antibody; WIT, warm ischemia time; CIT, cold ischemia time; DSA, donor specific antibody; †: 35 and 210 patients were screened for de novo DSA in the r-ATG group and basiliximab groups (two and 21 patients omitted), respectively.